Immune checkpoint inhibition in SCLC: Modest outcomes, many questionsNovember 4, 2019Lung CancerImmuno-oncologyOncology
Prior antibiotic use lowers checkpoint inhibitor response and survivalSeptember 12, 2019Immuno-oncologyLung CancerMelanomaOncology
Immune-related toxicities, hospitalization common with checkpoint inhibitor therapyAugust 12, 2019Lung CancerImmuno-oncology
Real-world data for immunotherapy-treated NSCLC found robustJuly 29, 2019Lung CancerImmuno-oncologyOncology
Skin plus GI adverse events with checkpoint inhibitors linked to risk of additional adverse eventsJune 14, 2019Immuno-oncologyOncology
EULAR issues guidelines on managing rheumatic complications of cancer immunotherapiesJune 14, 2019Immuno-oncologyOncology
Adding ipilimumab to nivolumab provides no benefit in SCC trialJune 12, 2019Lung CancerImmuno-oncologyOncology
Adjuvant immunotherapy results ‘encouraging’ in early NSCLCJune 11, 2019Lung CancerImmuno-oncologyOncology
Do some EGFR mutation subtypes benefit from immune checkpoint blockade?May 17, 2019Lung CancerImmuno-oncologyOncology
SRA737 + anti–PD-L1 therapy and low-dose gemcitabine shows early promise for SCLCApril 30, 2019Lung CancerImmuno-oncology
PACIFIC: Patient-reported outcomes unaffected by PD-L1 expressionApril 23, 2019Lung CancerImmuno-oncology
